Oncology Pathways in the US – Friend or Foe for Pharma?
By Tijana Ignjatovic, Lead Analyst
25 September 2015
I am a Lead Analyst for market access and strategy at Datamonitor Healthcare. My team covers a diverse range of topics r...
Read full bio
With the pharmaceutical industry constantly changing it’s important to keep up to date with the latest market access trends.
Our new analysis around oncology pathways in the US will help you identify strategies to mitigate the potential negative impact of these pathways on your oncology products.
This brochure takes you through the key findings contained within our new analysis, allowing you to take that first step into really understanding the implications of clinical pathways in oncology.
Our analysis will answer these key questions:
- Who is developing and using oncology clinical pathways?
- What impact have oncology pathways had on the oncology drug use so far?
- What strategies do pharmaceutical companies need to implement to mitigate the potential negative impact of oncology pathways on their oncology products or maximize opportunities?
Fill out the form now to download your free brochure >>